Alzheimer’s Disease Susceptibility Gene Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769)
Published version of a preprint
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative condition where the underlying etiology is still unclear. Investigating the potential influence of apolipoprotein E (APOE), a major genetic risk factor, on common blood biomarkers could provide a greater understanding of the mechanisms of AD and dementia risk. OBJECTIVE: Our objective was to conduct the largest (to date) single-protocol investigation of blood biomarkers in the context of APOE genotype, in UK Biobank. METHODS: After quality control and exclusions, data on 395,769 participants of White European ancestry were available for analysis. Linear regressions were used to test potential associations between APOE genotypes and biomarkers. RESULTS: Several biomarkers significantly associated with APOEɛ4 'risk' and ɛ2 'protective' genotypes (versus neutral ɛ3/ɛ3). Most associations supported previous data: for example, ɛ4 genotype was associated with elevated low-density lipoprotein cholesterol (LDL) (standardized beta [b] = 0.150 standard deviations [SDs] per allele, p < 0.001) and ɛ2 with lower LDL (b = -0.456 SDs, p < 0.001). There were however instances of associations found in unexpected directions: e.g., ɛ4 and increased insulin-like growth factor (IGF-1) (b = 0.017, p < 0.001) where lower levels have been previously suggested as an AD risk factor. CONCLUSION: These findings highlight biomarker differences in non-demented people at genetic risk for dementia. The evidence herein supports previous hypotheses of involvement from cardiometabolic and neuroinflammatory pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., Abraham, J., Adair, T., Aggarwal, R., Ahn, S. Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61728-0 · Cited by 14,070
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Role of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798
The genetic landscape of Alzheimer disease: clinical implications and perspectives
Van Cauwenberghe, C., Van Broeckhoven, C., & Sleegers, K. (2016) · Genetics in Medicine · doi:10.1038/gim.2015.117 · Cited by 863
Apolipoprotein E and Apolipoprotein E Receptors: Normal Biology and Roles in Alzheimer Disease
Holtzman, D. M., Herz, J., & Bu, G. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006312 · Cited by 782 · cited 1×
“The exact mechanisms by which APOE genotype influ-ences brain aging are unclear but probably due to pleiotropic pathways stemming from its core role in lipid metabolism [4].”
Genetics of 35 blood and urine biomarkers in the UK Biobank
Sinnott-Armstrong, N., Tanigawa, Y., Amar, D., Mars, N., Benner, C., Aguirre, M., Venkataraman, G. R., Wainberg, M., Ollila, H. M., Kiiskinen, T., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00757-z · Cited by 744
Age, APOE and sex: triad of risk of Alzheimer’s disease.
Riedel, B. C., Thompson, P. M., & Brinton, R. D. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.012 · Cited by 627
Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease
Whelan, C. D., Mattsson, N., Nagle, M. W., Vijayaraghavan, S., Hyde, C., Janelidze, S., Stomrud, E., Lee, J., Fitz, L., Samad, T. A., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0795-2 · Cited by 262
Self-citationAssociation of Chronic Low-grade Inflammation With Risk of Alzheimer Disease in ApoE4 Carriers
Tao, Q., Ang, T. F. A., DeCarli, C., Auerbach, S. H., Devine, S., Stein, T. D., Zhang, X., Massaro, J., Au, R., & Qiu, W. Q. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.3597 · Cited by 239
Research works printed but not linked: 35
- Kimoto, 2016, Serum insulin-like growth factor-I and amyloid beta protein in Alzheimer’s disease: Relationship with cognitive function, Psychogeriatrics, 16, 247, 10.1111/psyg.12149 · DOI
- Szalkai, 2017, Identifying combinatorial biomarkers by association rule mining in the CAMD Alzheimer’s database, Arch Gerontol Geriatr, 73, 300, 10.1016/j.archger.2017.08.006 · DOI
- Tynkkynen, 2018, Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer’s disease: A prospective study in eight cohorts, Alzheimers Dement, 14, 723, 10.1016/j.jalz.2018.01.003 · DOI · Paper page
- Yamazaki, 2016, Apolipoprotein E as a therapeutic target in Alzheimer’s disease: A review of research and clinical evidence, CNS Drugs, 30, 773, 10.1007/s40263-016-0361-4 · DOI · Paper page
- Bycroft, 2018, The UK Biobank resource with deep phenotyping and genomic data, Nature, 562, 203, 10.1038/s41586-018-0579-z · DOI · Paper page
- 10.1101/660506 · DOI · Paper page
- Lyall, 2019, Assessing for interaction between ɛ4, sex, and lifestyle on cognitive abilities, Neurology, 92, e2691, 10.1212/WNL.0000000000007551 · DOI
- Wilkinson, 2019, Identifying dementia outcomes in UK Biobank: A validation study of primary care, hospital admissions and mortality data, Eur J Epidemiol, 34, 557, 10.1007/s10654-019-00499-1 · DOI · Paper page
- Townsend, 1988, Health and Deprivation: Inequality and the North
- Lyall, 2019, The associations between self-reported depression, self-reported chronic inflammatory conditions and cognitive abilities in UK Biobank, Eur Psychiatry, 60, 63, 10.1016/j.eurpsy.2019.05.007 · DOI
- Lyall, 2017, Associations between single andmultiple cardiometabolic diseases and cognitive abilities in 474 129 UK Biobank participants, Eur Heart J, 38, 577
- Weroha, 2012, The insulin-like growth factor system in cancer, Endocrinol Metab Clin North Am, 41, 335, 10.1016/j.ecl.2012.04.014 · DOI · Paper page
- Wisdom, 2011, The effects of apolipoprotein E on non-impaired cognitive functioning: A meta-analysis, Neurobiol Aging, 32, 63, 10.1016/j.neurobiolaging.2009.02.003 · DOI · Paper page
- Vidal, 2016, Low serum insulin-like growth factor-I predicts cognitive decline in Alzheimer’s disease, J Alzheimers Dis, 52, 641, 10.3233/JAD-151162 · DOI · Paper page
- Lee, 2009, Adult hippocampal neurogenesis and related neurotrophic factors, BMB Rep, 42, 239, 10.5483/BMBRep.2009.42.5.239 · DOI · Paper page
- Egert, 2012, ApoE genotype: From geographic distribution to function and responsiveness to dietary factors, Proc Nutr Soc, 71, 410, 10.1017/S0029665112000249 · DOI · Paper page
- Maddock, 2015, 25-hydroxyvitamin D, APOE ɛ4 genotype and cognitive function: Findings from the 1958 British birth cohort, Eur J Clin Nutr, 69, 505, 10.1038/ejcn.2014.201 · DOI
- Wagner, 2018, Evaluation of the concurrent trajectories of cardiometabolic risk factors in the 14 years before dementia, JAMA Psychiatry, 75, 1033, 10.1001/jamapsychiatry.2018.2004 · DOI · Paper page
- Li, 2005, Serum cholesterol and risk of Alzheimer disease, Neurology, 65, 1045, 10.1212/01.wnl.0000178989.87072.11 · DOI · Paper page
- Reitz, 2010, Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease, Arch Neurol, 67, 1491, 10.1001/archneurol.2010.297 · DOI · Paper page
- Karjalainen, 2019, The effect of apolipoprotein E polymorphism on serum metabolome - a population-based 10-year follow-up study, Sci Rep, 9, 458, 10.1038/s41598-018-36450-9 · DOI · Paper page
- Tynkkynen, 2016, Apolipoproteins and HDL cholesterol do not associate with the risk of future dementia and Alzheimer’s disease: The National Finnish population study (FINRISK), Age (Dordr), 38, 465, 10.1007/s11357-016-9950-x · DOI
- Di Angelantonio, 2012, Lipid-related markers and cardiovascular disease prediction, JAMA, 307, 2499
- Slot, 2017, Apolipoprotein A1 in cerebrospinal fluid and plasma and progression to Alzheimer’s disease in non-demented elderly, J Alzheimers Dis, 56, 687, 10.3233/JAD-151068 · DOI · Paper page
- Kritharides, 2017, Effect of APOE ɛ genotype on lipoprotein(a) and the associated risk of myocardial infarction and aortic valve stenosis, J Clin Endocrinol Metab, 102, 3390, 10.1210/jc.2017-01049 · DOI
- Xing, 2013, Estrogen associated gene polymorphisms and their interactions in the progress of Alzheimer’s disease, Prog Neurobiol, 111, 53, 10.1016/j.pneurobio.2013.09.006 · DOI
- Chu, 2010, Bioavailable testosterone predicts a lower risk of Alzheimer’s disease in older men, J Alzheimers Dis, 21, 1335, 10.3233/JAD-2010-100027 · DOI · Paper page
- Panizzon, 2014, Interaction of APOE genotype and testosterone on episodic memory in middle-aged men, Neurobiol Aging, 35, e1, 10.1016/j.neurobiolaging.2013.12.025 · DOI
- Heneka, 2015, Neuroinflammation in Alzheimer’s disease, Lancet Neurol, 14, 388, 10.1016/S1474-4422(15)70016-5 · DOI · Paper page
- Martiskainen, 2018, Decreased plasma C-reactive protein levels in APOE ɛ4 allele carriers, Ann Clin Transl Neurol, 5, 1229, 10.1002/acn3.639 · DOI
- Yavuz, 2008, Serum elevated gamma glutamyltransferase levels may be a marker for oxidative stress in Alzheimer’s disease, Int Psychogeriatrics, 20, 815, 10.1017/S1041610208006790 · DOI · Paper page
- Pike, 2015, An alkaline phosphatase transport mechanism in the pathogenesis of Alzheimer’s disease and neurodegeneration, Chem Biol Interact, 226, 30, 10.1016/j.cbi.2014.12.006 · DOI
- Kaur, 2012, Cystatin C in Alzheimer’s disease, Front Mol Neurosci, 5, 79, 10.3389/fnmol.2012.00079 · DOI · Paper page
- Sundelöf, 2008, Serum cystatin C and the risk of Alzheimer disease in elderly men, Neurology, 71, 1072, 10.1212/01.wnl.0000326894.40353.93 · DOI · Paper page
- Li, 2017, Serum phosphorus levels and risk of incident Dementia, PLoS One, 12, e0171377, 10.1371/journal.pone.0171377 · DOI
Cited by
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“1, bilirubin, and ApoB, compared to APOE3 [310] Serum”
BackgroundApolipoprotein E in lipid metabolism and neurodegenerative disease
Yang, L. G., March, Z. M., Stephenson, R. A., & Narayan, P. S. (2023) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2023.05.002 · Cited by 286
“Given that APOE4 is a disease risk factor, not a causative gene, a genotype-specific preventative treatment must be highly tolerable and have a biomarker [157,158] that can indicate prevention of disease onset or progression.”
Metadata
- Authors
- Ferguson, A. C., Tank, R., Lyall, L. M., Ward, J., Celis-Morales, C., Strawbridge, R., Ho, F., Whelan, C. D., Gill, J., Welsh, P., Anderson, J. J., Mark, P. B., Mackay, D. F., Smith, D. J., Pell, J. P., Cavanagh, J., Sattar, N., & Lyall, D. M.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2020-08-18
- Volume
- 76
- Issue
- 4
- Pages
- 1541-1551
- ISSN
- 1387-2877
- 1875-8908
- Cited by
- 25
- References
- 16
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alzheimer’s Disease Susceptibility Gene Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769). https://app.cochat.ai/papers/10.3233/jad-200338
- The paper
- Ferguson, A. C., Tank, R., Lyall, L. M., Ward, J., Celis-Morales, C., Strawbridge, R., Ho, F., Whelan, C. D., Gill, J., Welsh, P., Anderson, J. J., Mark, P. B., Mackay, D. F., Smith, D. J., Pell, J. P., Cavanagh, J., Sattar, N., & Lyall, D. M. (2020). Alzheimer’s Disease Susceptibility Gene Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769). Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-200338
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.